BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age

JAMA Netw Open. 2024 Dec 2;7(12):e2449944. doi: 10.1001/jamanetworkopen.2024.49944.

Affiliations

¹ Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
² Kaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu, Hawaii.
³ Pfizer Inc, New York, New York.
⁴ Southern California Permanente Medical Group, Harbor City, California.

No abstract available

Plain language summary

This case-control study of US children examines vaccine effectiveness rates of a messenger RNA vaccine during the 2023-2024 respiratory virus season.